Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Type 1, or insulin-dependent diabetes, is an autoimmune disease that culminates in the destruction of insulin-producing β-cells in the islets of the pancreas. Studies in the nonobese diabetic (NOD) mouse model of spontaneous type 1 diabetes provide “proof-of-concept” that the disease is preventable (1). People with type 1 diabetes and their relatives, researchers, government, and industry are eager to move forward and test candidate intervention/prevention therapies in humans. Such therapies may entail risks, including accelerated loss of β-cell function, malignancy, and infection. Scientifically and ethically, investigators are obliged to maximize the information gained from intervention trials and minimize risks. One way of achieving this is by standardizing trial protocols. Standardization of islet autoantibody assays (2–13) and of the intravenous glucose tolerance test for measuring first-phase insulin response (14–18) has been a major advance, allowing stratification for disease risk among relatives. The literature on intervention trials in newly diagnosed type 1 diabetic patients (19–44) reveals that entry criteria, trial design and duration, and outcome measures differ considerably. Adoption of standardized protocols would permit comparative and pooled data analysis and facilitate evaluation of potential therapies. Our purpose here is to highlight issues pertaining to trial variables and suggest ways of standardizing protocols for phase I and II intervention trials in newly diagnosed patients. These issues will be discussed under three major headings: trial subjects, trial design, and trial outcome measures. ### Diagnosis of diabetes #### Background. Type 1 diabetes can have different clinical presentations that presumably reflect the nature of the underlying disease pathology, to which we have no direct access. Some patients present acutely with dehydration and ketoacidosis, whereas others have minimal or no symptoms (45,46). Natural history studies have indicated that these differences may correlate with the rate of loss of β-cell function and residual β-cell function, determined …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verge, C. F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H. P., Eisenbarth, G. S., & Jackson, R. A. (1996) · Diabetes · doi:10.2337/diab.45.7.926 · Cited by 827
The NOD mouse model of type 1 diabetes: As good as it gets?
Atkinson, M. A., & Leiter, E. H. (1999) · Nature Medicine · doi:10.1038/9442 · Cited by 588
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Zimmet, P., Tuomi, T., Mackay, I. R., Rowley, M. J., Knowles, W., Cohen, M., & Lang, D. A. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00275.x · Cited by 413
The Canadian-European Randomized Control Trial Group (1988) · Diabetes · doi:10.2337/diab.37.11.1574 · Cited by 164
Schmidli, R. S., Colman, P. G., Bonifacio, E., Franco Bottazzo, G., & Harrison, L. C. (1994) · Diabetes · doi:10.2337/diab.43.8.1005 · Cited by 86
Self-citation
Cited by
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
A practical review of C-peptide testing in diabetes
Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Self-citationGreenbaum, C. J., Mandrup-Poulsen, T., McGee, P. F., Battelino, T., Haastert, B., Ludvigsson, J., Pozzilli, P., Lachin, J. M., Kolb, H., & The Type 1 Diabetes Trial Net Research Group and the European C-Peptide Trial Study Group (2008) · Diabetes Care · doi:10.2337/dc07-2451 · Cited by 285
Self-citationMaddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
Metadata
- Authors
- Greenbaum, C. J., Harrison, L. C., & on behalf of the Immunology of Diabetes Society
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2003-05-01
- Volume
- 52
- Issue
- 5
- Pages
- 1059-1065
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2001834753
- Cited by
- 76
- References
- 8
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/diabetes.52.5.1059
- The paper
- Greenbaum, C. J., Harrison, L. C., & on behalf of the Immunology of Diabetes Society. (2003). Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes. Diabetes. https://doi.org/10.2337/diabetes.52.5.1059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.